相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells
Heena Saini et al.
CANCER CELL INTERNATIONAL (2021)
The relationship between the expression of Ki-67 and the prognosis of osteosarcoma
Ming Zeng et al.
BMC CANCER (2021)
Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
Kazuhiko Hashimoto et al.
EUROPEAN JOURNAL OF HISTOCHEMISTRY (2021)
Assessing PET Parameters in Oncologic 18F-FDG Studies
Ismet Sarikaya et al.
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY (2020)
Outcomes of comprehensive treatment for primary osteosarcoma
Kazuhiko Hashimoto et al.
SAGE OPEN MEDICINE (2020)
F-18-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma
James C. Davis et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Remy Thomas et al.
FRONTIERS IN IMMUNOLOGY (2018)
Ki67 targeted strategies for cancer therapy
C. Yang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Mutant p53 as a target for cancer treatment
Michael J. Duffy et al.
EUROPEAN JOURNAL OF CANCER (2017)
MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1
Kunio Iura et al.
VIRCHOWS ARCHIV (2017)
Correlation between osteosarcoma and the expression of WWOX and p53
Pingtao Liu et al.
ONCOLOGY LETTERS (2017)
SRCIN1 Suppressed Osteosarcoma Cell Proliferation and Invasion
Peng Wang et al.
PLOS ONE (2016)
Coexistence of her2, ki67, and p53 in osteosarcoma: A strong prognostic factor
Keykhosro Mardanpour et al.
NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES (2016)
The MAGE protein family and cancer
Jenny L. Weon et al.
CURRENT OPINION IN CELL BIOLOGY (2015)
Immunotherapeutic Approaches to Sarcoma
Melissa Burgess et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine
Takuro Saito et al.
VACCINE (2014)
Induction of a specific CD8+T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma
Binghao Li et al.
ONCOTARGET (2014)
Initial Metabolic Tumor Volume Measured by 18F-FDG PET/CT Can Predict the Outcome of Osteosarcoma of the Extremities
Byung Hyun Byun et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
A systematic review of p53 as a biomarker of survival in patients with osteosarcoma
Hai-Liang Fu et al.
TUMOR BIOLOGY (2013)
NY-ESO-1 expression in sarcomas A diagnostic marker and immunotherapy target
Jin-Ping Lai et al.
ONCOIMMUNOLOGY (2012)
p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in Esophageal Squamous Cell Carcinoma
Noushin Taghavi et al.
BMC CANCER (2010)
Bone Cancer
J. Sybil Biermann et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2010)
p53 Research: The Past Thirty Years and the Next Thirty Years
David Lane et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
F-18-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma
Colleen M. Costelloe et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J
Yukihide Iwamoto et al.
JOURNAL OF ORTHOPAEDIC SCIENCE (2009)
The first 30 years of p53: growing ever more complex
Arnold J. Levine et al.
NATURE REVIEWS CANCER (2009)
A review of clinical and molecular prognostic factors in osteosarcoma
Jonathan C. M. Clark et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Primary metastatic osteosarcoma:: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols
L Kager et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
MJ Scanlan et al.
IMMUNOLOGICAL REVIEWS (2002)